Posted by Michael Wonder on 01 Nov 2022
Schedule of Pharmaceutical Benefits - 1 November 2022
1 November 2022 - The November 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The November issue of the Schedule includes a number of major new/revised listings:
- Atezolizumab (Tecentriq) - new indication
- Burosumab (Crysvita) - new medicine
- Cemiplimab (Libtayo) - new medicine (2 indications)
- Tepotinib hydrochloride monohydrate (Tepmetko) - new medicine
